Wedbush Morgan downgrades Inspire Pharmaceuticals (Nasdaq: ISPH) from Strong Buy To Buy, but maintaining its $22 fair value valuation.

This article: 152 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE